Characteristic | Deaths (n = 15) | Nondeaths (n = 44) | |||
---|---|---|---|---|---|
NO. of Patients | NO. (%) | NO. of Patients | NO. (%) | P Value | |
Course of illness | |||||
length of hospital stay (IQR) | 10 (3–15) | 25.5 (19.25–31.75) | 0 | ||
Cough duration before the PICU (IQR) | 11 (7–14) | 14 (8–19.75) | 0.061 | ||
length of PICU stay (IQR) | 3 (2–12) | 13.5 (8–17) | 0.003 | ||
Leukocytosis (WBC ≥ 30 × 109 /L.) | 14 | 93.33% | 19 | 43.18% | 0.001 |
Leukocytosis (WBC ≥ 50 × 109 /L.) | 13 | 86.67% | 7 | 15.91% | 0 |
Highest WBC count | 77.33 ± 28.56 | 30.52 ± 16.46 | 0 | ||
Highest lymphocyte count | 29.59 ± 13.59 | 16.19 ± 9.20 | 0 | ||
Highest Platelet count | 740.47 ± 199.93 | 696.05 ± 153.47 | 0.375 | ||
Congenital heart disease (ASD or PDA) | 5 (13) | 38.46% | 15 (36) | 41.66% | 1 |
Pulmonary hypertension | 8 (14) | 57.14% | 3 (36) | 8.33% | 0.001 |
Pulmonary hypertension without CHD | 3 (8) | 44.40% | 0 (3) | 0 | 0.214 |
Pneumonia | 15 | 100% | 44 | 100% | |
Co-infectious with clearly pathogen | 13 | 86.60% | 38 | 86.36% | 0.976 |
Consolidation of lung | 9 | 60.00% | 23 | 52.27% | 0.604 |
Convulsions | 2 | 13.30% | 8 | 18.20% | 0.666 |
Pertussis encephalopathy | 5 | 33.30% | 21 | 47.70% | 0.332 |
Co- morbidity | 12 | 80.00% | 24 | 54.54% | 0.081 |
Treatment | |||||
Received macrolide antibiotics | 15 | 100% | 44 | 100% | |
Days to macrolide initiation (IQR) | 8 (6–11) | 10.5 (9–15) | 0.012 | ||
Received steroids | 6 | 40.00% | 13 | 29.50% | 0.454 |
Respiratory support (invasive or/and noninvasive) | 15 | 100% | 36 + 4 | 90.90% | 0.226 |
intubated | 15 | 100% | 36 | 81.80% | 0.076 |
Ventilator time | 3 (2–12) | 8 (5–13.75) | 0.412 | ||
Exchange transfusion | 3 | 20.00% | 2 | 4.55% | 0.063 |
ECMO | 1 | 0.07% | 0 | 0.084 |